Clinical trials
Solid Tumors (Phase 1) clinical trials
Below are recruiting solid tumors (phase 1) clinical trials, each written for real people, not researchers. We’re tracking 527 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06376136RecruitingPhase 1/Phase 2
Combination therapy for advanced HER2-positive cancers
This trial tests a new combination of two drugs, BAT8010 and BAT1006, for people with advanced solid tumors that have HER2 expression. It aims to see if this combination is safe and effective for those who have run out of standard treatment options.
Guangzhou, GuangdongAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75 - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT06717750RecruitingPhase 1
Study of a new drug for advanced solid tumors
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT06208657RecruitingPhase 1/Phase 2
Personalized cancer therapy for kids and teens
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
Newcastle, New South WalesAges birth–21 years - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT06224387RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug, CTS2190, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if the drug is safe and effective.
Luoyang, HenanAges 18 years+ - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT06898255RecruitingPhase 1
GFS202A for advanced solid tumors with weight loss
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
Guangzhou, GuangdongAges 18–80 - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT00571389Recruiting
Collecting blood cells from people with cancer or COVID-19
This study collects blood cells using a special blood-draw procedure called leukapheresis (for some participants) and other samples. It aims to better understand cancer and immune-related cells, which may help researchers design or improve future treatments.
Huntersville, North CarolinaAges 5 years+ - NCT05483400RecruitingPhase 2
Atezolizumab and tiragolumab study for several solid tumors
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
GroningenAges 18 years+
Hear when a new Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumors (phase 1)?
- Yes. Clin2 currently lists 527 recruiting solid tumors (phase 1) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumors (phase 1) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumors (phase 1) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.